Shenzhen Neptunus Bioengineering Co., Ltd.

SZSE:000078 Stock Report

Market Cap: CN¥6.6b

Shenzhen Neptunus Bioengineering Past Earnings Performance

Past criteria checks 0/6

Shenzhen Neptunus Bioengineering's earnings have been declining at an average annual rate of -66.6%, while the Healthcare industry saw earnings growing at 2% annually. Revenues have been declining at an average rate of 3.5% per year.

Key information

-66.6%

Earnings growth rate

-66.9%

EPS growth rate

Healthcare Industry Growth7.0%
Revenue growth rate-3.5%
Return on equity-42.5%
Net Margin-5.4%
Next Earnings Update29 Apr 2025

Recent past performance updates

Recent updates

Is Shenzhen Neptunus Bioengineering (SZSE:000078) A Risky Investment?

Dec 18
Is Shenzhen Neptunus Bioengineering (SZSE:000078) A Risky Investment?

Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Revenues Are Not Doing Enough For Some Investors

Oct 28
Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Revenues Are Not Doing Enough For Some Investors

Here's Why Shenzhen Neptunus Bioengineering (SZSE:000078) Is Weighed Down By Its Debt Load

Jul 15
Here's Why Shenzhen Neptunus Bioengineering (SZSE:000078) Is Weighed Down By Its Debt Load

There Is A Reason Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Price Is Undemanding

Jun 07
There Is A Reason Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Price Is Undemanding

Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Share Price Is Matching Sentiment Around Its Revenues

Mar 05
Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Share Price Is Matching Sentiment Around Its Revenues

Revenue & Expenses Breakdown

How Shenzhen Neptunus Bioengineering makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSE:000078 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2432,331-1,7322,35043
30 Jun 2433,096-1,7322,45846
31 Mar 2434,549-1,7222,53947
31 Dec 2336,419-1,6902,74848
30 Sep 2337,520-1,0702,72948
30 Jun 2339,667-1,0532,85545
31 Mar 2338,591-1,0232,87348
01 Jan 2337,835-1,0272,86048
30 Sep 2239,234122,54428
30 Jun 2238,937672,70641
31 Mar 2240,121732,75138
01 Jan 2241,054932,78139
30 Sep 2142,053-2753,00452
30 Jun 2142,395-2762,89043
31 Mar 2142,091-2762,93443
31 Dec 2040,022-2892,75338
30 Sep 2039,535412,95750
30 Jun 2038,5081312,95338
31 Mar 2039,0131533,00939
31 Dec 1941,4932063,14042
30 Sep 1941,2603483,25644
30 Jun 1941,6812923,26148
31 Mar 1939,7233943,12655
31 Dec 1838,3814153,01245
30 Sep 1836,6086572,74761
30 Jun 1833,2697272,49670
31 Mar 1829,9546972,16050
01 Jan 1824,9406361,86850
30 Sep 1719,5936021,51117
30 Jun 1716,4685541,2830
31 Mar 1714,6674711,2040
31 Dec 1613,6064181,1650
30 Sep 1613,0653521,1340
30 Jun 1612,0815201,1070
31 Mar 1611,5724871,1310
31 Dec 1511,1184751,1140
30 Sep 1510,8093201,0900
30 Jun 1510,505261,0910
31 Mar 1510,177251,0410
31 Dec 149,802241,0400
30 Sep 149,2931139940
30 Jun 148,9221191,0150
31 Mar 148,4271199560

Quality Earnings: 000078 is currently unprofitable.

Growing Profit Margin: 000078 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 000078 is unprofitable, and losses have increased over the past 5 years at a rate of 66.6% per year.

Accelerating Growth: Unable to compare 000078's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 000078 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-5.7%).

Return on Equity

High ROE: 000078 has a negative Return on Equity (-42.46%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 21:12
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shenzhen Neptunus Bioengineering Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhouyu DengBOCI Research Ltd.
Zhouyu DengGuosen Securities Co., Ltd.